Acrivastine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Allergic conditions

Adult: 8 mg, as necessary, up to tid.
Child: ≥12 yr Same as adult dose.

Renal Impairment

Severe: Contraindicated.

Administration

May be taken with or without food.

Contraindications

Severe renal impairment.

Special Precautions

Patient w/ porphyria, epilepsy. Renal impairment. Elderly. Pregnancy and lactation.

Adverse Reactions

Anticholinergic effects, GI disturbance, headache, psychomotor impairment, somnolence, dry mouth, rash, blurred vision, urinary retention. Rarely, dizziness, dyspnoea, angioedema.

Pregnancy Category (US FDA)

PO: B (FDA Pregnancy Category B for acrivastine/pseudoephedrine hydrochloride combination.)

Patient Counseling Information

This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.

Drug Interactions

May produce additional mental depression w/ CNS depressants.

Food Interaction

May produce additional mental depression w/ alcohol.

Action

Description: Acrivastine, an alkylamine, is a second generation antihistamine structurally related to triprolidine. It is a competitive antagonist of H₁-receptors but lacks anticholinergic effects.
Onset: 15 min.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: Approx 1.5 hr.
Distribution: Volume of distribution: Approx 0.5-0.8 L/kg. Plasma protein binding: Approx 50%, mainly to albumin.
Metabolism: Minimally metabolised in the liver into its active metabolite, propionic acid.
Excretion: Via urine (84%) and faeces (13%). Elimination half-life: Approx 2-4 hr.

Chemical Structure

Storage

Store at or below 30°C.

MIMS Class

Antihistamines & Antiallergics

ATC Classification

R06AX18 - acrivastine ; Belongs to the class of other antihistamines for systemic use.

References

Anon. Acrivastine and Pseudoephedrine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/08/2016.

Buckingham R (ed). Acrivastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2016.

Joint Formulary Committee. Acrivastine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/08/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Acrivastine. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 09/08/2016.

Disclaimer: This information is independently developed by MIMS based on Acrivastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com